Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice

Vaccine

Volumn 30, Issue 22, 2012, Pages 3311-3319

  Lumsden, Joanne M ^a   Nurmukhambetova, Saule ^a   Klein, Jennifer H ^a   Sattabongkot, Jetsumon ^b,d   Bennett, Jason W ^a   Bertholet, Sylvie ^c   Fox, Christopher B ^c   Reed, Steven G ^c   Ockenhouse, Christian F ^a   Howard, Randall F ^c   Polhemus, Mark E ^a   Yadava, Anjali ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Armed Forces Institute of Research   (Thailand)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Circumsporozoite protein; Immunogenicity; Malaria; Plasmodium vivax; TLR agonists; Vaccine

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; INTERLEUKIN 2; MALARIA VACCINE; RECOMBINANT PROTEIN; RESIQUIMOD; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VMP 001;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; EMULSIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERLEUKIN-2; MALARIA VACCINES; MICE; MICE, INBRED C57BL; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 84859818500     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.004     Document Type: Article

References (57)

1. Yadava A., Sattabongkot J., Washington M.A., Ware L.A., Majam V., Zheng H., et al. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 2007, 75(March (3)):1177-1185.
2. Bell B.A., Wood J.F., Bansal R., Ragab H., Cargo J., Washington M.A., et al. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax. Vaccine 2009, 27(February (9)):1448-1453.
3. Becker C.E., O'Neill L.A. Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs. Semin Immunopathol 2007, 29(September (3)):239-248.
4. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388(July (6640)):394-397.
5. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282(December (5396)):2085-2088.
6. Ozato K., Tsujimura H., Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques 2002, (October (Suppl.)). 66-68, 70, 2 passim.
7. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2003, 2(April (2)):219-229.
8. Baldridge J.R., McGowan P., Evans J.T., Cluff C., Mossman S., Johnson D., et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004, 4(July (7)):1129-1138.
9. Cluff C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2009, 667:111-123.
10. Baldwin S.L., Bertholet S., Kahn M., Zharkikh I., Ireton G.C., Vedvick T.S., et al. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 2009, 27(May (23)):3063-3071.
11. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6(1):e16333.
12. Bertholet S., Ireton G.C., Ordway D.J., Windish H.P., Pine S.O., Kahn M., et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2010, 2(October (53)):53-74.
13. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27(October (43)):5956-5963.
14. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditlev S.B., Christiansen M., et al. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 - a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29(April (17)):3284-3292.
15. Bertholet S., Goto Y., Carter L., Bhatia A., Howard R.F., Carter D., et al. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 2009, 25(September):25.
16. Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168(May (9)):4531-4537.
17. Jarrossay D., Napolitani G., Colonna M., Sallusto F., Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001, 31(November (11)):3388-3393.
18. Gorden K.B., Gorski K.S., Gibson S.J., Kedl R.M., Kieper W.C., Qiu X., et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005, 174(February (3)):1259-1268.
19. Hattermann K., Picard S., Borgeat M., Leclerc P., Pouliot M., Borgeat P. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J 2007, 21(May (7)):1575-1585.
20. Doxsee C.L., Riter T.R., Reiter M.J., Gibson S.J., Vasilakos J.P., Kedl R.M. The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8-dendritic cells. J Immunol 2003, 171(August (3)):1156-1163.
21. Gorden K.K., Qiu X., Battiste J.J., Wightman P.P., Vasilakos J.P., Alkan S.S. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines. J Immunol 2006, 177(December (11)):8164-8170.
22. Tomai M.A., Miller R.L., Lipson K.E., Kieper W.C., Zarraga I.E., Vasilakos J.P. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines 2007, 6(October (5)):835-847.
23. Wagner T.L., Ahonen C.L., Couture A.M., Gibson S.J., Miller R.L., Smith R.M., et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999, 191(January (1)):10-19.
24. Bishop G.A., Hsing Y., Hostager B.S., Jalukar S.V., Ramirez L.M., Tomai M.A. Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol 2000, 165(November (10)):5552-5557.
25. Tomai M.A., Imbertson L.M., Stanczak T.L., Tygrett L.T., Waldschmidt T.J. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000, 203(July (1)):55-65.
26. Vasilakos J.P., Smith R.M., Gibson S.J., Lindh J.M., Pederson L.K., Reiter M.J., et al. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cell Immunol 2000, 204(August (1)):64-74.
27. Johansen P., Senti G., Martinez Gomez J.M., Storni T., von Beust B.R., Wuthrich B., et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005, 35(December (12)):1591-1598.
28. Thomsen L.L., Topley P., Daly M.G., Brett S.J., Tite J.P. Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 2004, 22(April (13-14)):1799-1809.
29. Otero M., Calarota S.A., Felber B., Laddy D., Pavlakis G., Boyer J.D., et al. Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model. Vaccine 2004, 22(April (13-14)):1782-1790.
30. Smorlesi A., Papalini F., Orlando F., Donnini A., Re F., Provinciali M. Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma. Gene Ther 2005, 12(September (17)):1324-1332.
31. Bernstein D.I., Miller R.L., Harrison C.J. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis 1993, 167(March (3)):731-735.
32. Harrison C.J., Miller R.L., Bernstein D.I. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001, 19(February (13-14)):1820-1826.
33. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 2006, 203(May (5)):1249-1258.
34. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Kedl R.M., Mattapallil J.J., et al. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 2005, 102(October (42)):15190-15194.
35. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108(July (2)):544-550.
36. Vanderberg J.P., Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol 2004, 34(August (9)):991-996.
37. Bouharoun-Tayoun H., Druilhe P. Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 1992, 60(April (4)):1473-1481.
38. Danforth H.D., Aikawa M., Cochrane A.H., Nussenzweig R.S. Sporozoites of mammalian malaria: attachment to, interiorization and fate within macrophages. J Protozool 1980, 27(May (2)):193-202.
39. Schwenk R., Asher L.V., Chalom I., Lanar D., Sun P., White K., et al. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine. Parasite Immunol 2003, 25(January (1)):17-25.
40. Ferreira A., Schofield L., Enea V., Schellekens H., van der Meide P., Collins W.E., et al. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 1986, 232(May (4752)):881-884.
41. Nardin E.H., Nussenzweig R.S. T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages. Annu Rev Immunol 1993, 11:687-727.
42. Sun P., Schwenk R., White K., Stoute J.A., Cohen J., Ballou W.R., et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 2003, 171(December (12)):6961-6967.
43. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200(August (3)):337-346.
44. Reece W.H., Pinder M., Gothard P.K., Milligan P., Bojang K., Doherty T., et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004, 10(April (4)):406-410.
45. Mazier D., Renia L., Nussler A., Pied S., Marussig M., Goma J., et al. Hepatic phase of malaria is the target of cellular mechanisms induced by the previous and the subsequent stages. A crucial role for liver nonparenchymal cells. Immunol Lett 1990, 25(August (1-3)):65-70.
46. Korten S., Anderson R.J., Hannan C.M., Sheu E.G., Sinden R., Gadola S., et al. Invariant Valpha14 chain NKT cells promote Plasmodium berghei circumsporozoite protein-specific gamma interferon- and tumor necrosis factor alpha-producing CD8+ T cells in the liver after poxvirus vaccination of mice. Infect Immun 2005, 73(February (2)):849-858.
47. Lumsden J.M., Schwenk R.J., Rein L.E., Moris P., Janssens M., Ofori-Anyinam O., et al. Protective immunity induced with the RTS,S/AS vaccine is associated with IL-2 and TNF-alpha producing effector and central memory CD4 T Cells. PLoS One 2011, 6(7):e20775.
48. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8(April (4)):247-258.
49. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007, 204(June (6)):1405-1416.
50. Akondy R.S., Monson N.D., Miller J.D., Edupuganti S., Teuwen D., Wu H., et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009, 183(December (12)):7919-7930.
51. Derrick S.C., Yabe I.M., Yang A., Morris S.L. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011, 29(April (16)):2902-2909.
52. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(July (7)):843-850.
53. Ramharter M., Winkler H., Kremsner P.G., Adegnika A.A., Willheim M., Winkler S. Age-dependency of Plasmodium falciparum-specific and non-specific T cell cytokine responses in individuals from a malaria-endemic area. Eur Cytokine Netw 2005, 16(June (2)):135-143.
54. Wille-Reece U., Wu C.Y., Flynn B.J., Kedl R.M., Seder R.A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005, 174(June (12)):7676-7683.
55. Weeratna R.D., Makinen S.R., McCluskie M.J., Davis H.L. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005, 23(November (45)):5263-5270.
56. Gorden K.K., Qiu X.X., Binsfeld C.C., Vasilakos J.P., Alkan S.S. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol 2006, 177(November (10)):6584-6587.
57. Forward N.A., Furlong S.J., Yang Y., Lin T.J., Hoskin D.W. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells. J Leukoc Biol 2009, 87(January (1)):117-125.